Floatz logo

S 64315

Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Essen Biotech
Phase 1/2CC
Eb-Select Single-Target Car-Nk Cells
Essen Biotech
Phase 1/2CC
Cyclophosphamide
Essen Biotech
Phase 1/2CC
Dual-Target Antigen-Selected Car-Nk
Essen Biotech
Phase 1/2CC
Enoxaparin
Medical University of Gdansk
N/AD
Rivaroxaban
Medical University of Gdansk
N/AD
Apixaban
Medical University of Gdansk
N/AD

Same molecule, other indications

S 64315 is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
59 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
47 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →